A phase 4, open-label exemestane adjuvant safety surveillance program: Adjuvant exemestane (Aromasin) treatment following previous treatment with tamoxifen in postmenopausal women with estrogen sensitive primary breast cancer (IES [Intergroup Exemestane Study] inclusion criteria)

Trial Profile

A phase 4, open-label exemestane adjuvant safety surveillance program: Adjuvant exemestane (Aromasin) treatment following previous treatment with tamoxifen in postmenopausal women with estrogen sensitive primary breast cancer (IES [Intergroup Exemestane Study] inclusion criteria)

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2008

At a glance

  • Drugs Exemestane (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Sep 2008 Actual patient number (1549) added as reported by ClinicalTrials.gov.
    • 23 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top